Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns

REMS with provider and pharmacy certification could help address hepatotoxicity worries for the tenosynovial giant cell tumor treatment, but Daiichi likely also will face clinical benefit questions during advisory committee review.